Royalty Pharma logo

RPRX - Royalty Pharma Share Price

$37.68 0.5  1.3%

Last Trade - 03/08/21

Large Cap
Market Cap £22.02bn
Enterprise Value £28.07bn
Revenue £1.58bn
Position in Universe 440th / 7030
Unlock RPRX Revenue
Relative Strength (%)
1m -12.9%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -30.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 1,598 1,795 1,814 2,122 2,080 2,286 +9.9%
+19.0 +70.5 -60.1 +75.0 +11.6
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, RoyaltyPharma plc revenues increased 14% to $573M. Net incomeapplicable to common stockholders increased from $0K to$69.1M. Revenues reflect Income from financial royaltyassets increase of 14% to $529.6M, Other royalty incomeincrease from $3.1M to $7.3M, Revenue from intangibleroyalty assets increase of 3% to $36.1M. Dividend per sharetotaled to $0.17.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


RPRX Revenue Unlock RPRX Revenue

Net Income

RPRX Net Income Unlock RPRX Revenue

Normalised EPS

RPRX Normalised EPS Unlock RPRX Revenue

PE Ratio Range

RPRX PE Ratio Range Unlock RPRX Revenue

Dividend Yield Range

RPRX Dividend Yield Range Unlock RPRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
RPRX EPS Forecasts Unlock RPRX Revenue
Profile Summary

Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
No. of Shareholders: n/a
No. of Employees: 51
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 821,367,704
Free Float (0.0%)
Eligible for
RPRX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for RPRX
Upcoming Events for RPRX
Wednesday 11th August, 2021
Q2 2021 Royalty Pharma PLC Earnings Release
Wednesday 11th August, 2021
Q2 2021 Royalty Pharma PLC Earnings Call
Thursday 19th August, 2021
Dividend For RPRX.OQ - 0.1700 USD
Monday 8th November, 2021 Estimate
Q3 2021 Royalty Pharma PLC Earnings Release
Frequently Asked Questions for Royalty Pharma
What is the Royalty Pharma share price?

As of 03/08/21, shares in Royalty Pharma are trading at $37.68, giving the company a market capitalisation of £22.02bn. This share price information is delayed by 15 minutes.

How has the Royalty Pharma share price performed this year?

Shares in Royalty Pharma are currently trading at $37.68 and the price has moved by -13.57% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Royalty Pharma price has moved by -35.21% over the past year.

What are the analyst and broker recommendations for Royalty Pharma?

Of the analysts with advisory recommendations for Royalty Pharma, there are there are currently 1 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Royalty Pharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Royalty Pharma next release its financial results?

Royalty Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Royalty Pharma dividend yield?

The Royalty Pharma dividend yield is 1.26% based on the trailing twelve month period.

Does Royalty Pharma pay a dividend?

Last year, Royalty Pharma paid a total dividend of 0.47, and it currently has a trailing dividend yield of 1.26%. Looking ahead, shares in Royalty Pharma are due to go ex-dividend on 2021-08-19 and the next dividend pay date is 2021-09-15.

When does Royalty Pharma next pay dividends?

Royalty Pharma are due to go ex-dividend on 2021-08-19 and the next dividend pay date is 2021-09-15. The historic dividend yield on Royalty Pharma shares is currently 1.26%.

How do I buy Royalty Pharma shares?

To buy shares in Royalty Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Royalty Pharma?

Shares in Royalty Pharma are currently trading at $37.68, giving the company a market capitalisation of £22.02bn.

Where are Royalty Pharma shares listed? Where are Royalty Pharma shares listed?

Here are the trading details for Royalty Pharma:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: RPRX
What kind of share is Royalty Pharma?

Based on an overall assessment of its quality, value and momentum, Royalty Pharma is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Royalty Pharma share price forecast 2021?

Shares in Royalty Pharma are currently priced at $37.68. At that level they are trading at 41.66% discount to the analyst consensus target price of 0.00.

Analysts covering Royalty Pharma currently have a consensus Earnings Per Share (EPS) forecast of 2.753 for the next financial year.

How can I tell whether the Royalty Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Royalty Pharma. Over the past six months, the relative strength of its shares against the market has been -31.87%. At the current price of $37.68, shares in Royalty Pharma are trading at -14.86% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Royalty Pharma PE Ratio?

The Royalty Pharma PE ratio based on its reported earnings over the past 12 months is 21.46. The shares are currently trading at $37.68.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Royalty Pharma?

Royalty Pharma's management team is headed by:

Pablo Legorreta - CHM
Terrance Coyne - CFO
Christopher Hite - VCH
George Lloyd - EVP
James Reddoch - EVP
Errol De Souza - IND
M. Germano Giuliani - DRC
Rory Riggs - DRC
Molly Chiaramonte - SVP
Marshall Urist - SVP
Bonnie Bassler - IND
Henry Fernandez - LED
Who are the major shareholders of Royalty Pharma?

Here are the top five shareholders of Royalty Pharma based on the size of their shareholding:

Morgan Stanley Investment Management Inc. (US) Investment Advisor/Hedge Fund
Percentage owned: 11.1% (47.4m shares)
Nogra Group Sicaf SIF S.A. Corporation
Percentage owned: 10.85% (46.3m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 6.41% (27.4m shares)
Adage Capital Management, L.P. Hedge Fund
Percentage owned: 5.78% (24.7m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 5.27% (22.5m shares)
Similar to RPRX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.